nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—Hydrocortisone—psoriasis	0.415	1	CrCtD
Levonorgestrel—PGR—Betamethasone—psoriasis	0.0526	0.23	CbGbCtD
Levonorgestrel—SHBG—Hydrocortisone—psoriasis	0.0472	0.207	CbGbCtD
Levonorgestrel—PGR—Dexamethasone—psoriasis	0.0306	0.134	CbGbCtD
Levonorgestrel—CYP19A1—Betamethasone—psoriasis	0.0296	0.13	CbGbCtD
Levonorgestrel—Danazol—Hydrocortisone—psoriasis	0.0233	0.0945	CrCrCtD
Levonorgestrel—Norethindrone—Hydrocortisone—psoriasis	0.0203	0.0822	CrCrCtD
Levonorgestrel—Danazol—Prednisone—psoriasis	0.0201	0.0814	CrCrCtD
Levonorgestrel—CYP19A1—Dexamethasone—psoriasis	0.0172	0.0754	CbGbCtD
Levonorgestrel—Progesterone—Hydrocortisone—psoriasis	0.0171	0.0692	CrCrCtD
Levonorgestrel—Testosterone Propionate—Hydrocortisone—psoriasis	0.0171	0.0692	CrCrCtD
Levonorgestrel—Methyltestosterone—Hydrocortisone—psoriasis	0.0166	0.0675	CrCrCtD
Levonorgestrel—Testosterone—Hydrocortisone—psoriasis	0.0148	0.0601	CrCrCtD
Levonorgestrel—Progesterone—Prednisolone—psoriasis	0.0143	0.0582	CrCrCtD
Levonorgestrel—Methyltestosterone—Prednisone—psoriasis	0.0143	0.0581	CrCrCtD
Levonorgestrel—Methyltestosterone—Prednisolone—psoriasis	0.014	0.0567	CrCrCtD
Levonorgestrel—Hydrocortisone—Dexamethasone—psoriasis	0.0129	0.0524	CrCrCtD
Levonorgestrel—Hydrocortisone—Betamethasone—psoriasis	0.0129	0.0524	CrCrCtD
Levonorgestrel—Hydrocortisone—Triamcinolone—psoriasis	0.0126	0.0512	CrCrCtD
Levonorgestrel—Testosterone—Prednisolone—psoriasis	0.0124	0.0505	CrCrCtD
Levonorgestrel—Hydrocortisone—Prednisone—psoriasis	0.012	0.0486	CrCrCtD
Levonorgestrel—Hydrocortisone—Prednisolone—psoriasis	0.0117	0.0475	CrCrCtD
Levonorgestrel—CYP3A4—Calcitriol—psoriasis	0.00979	0.0428	CbGbCtD
Levonorgestrel—CYP3A4—Methoxsalen—psoriasis	0.00761	0.0333	CbGbCtD
Levonorgestrel—CYP3A4—Cholecalciferol—psoriasis	0.00504	0.0221	CbGbCtD
Levonorgestrel—CYP3A4—Triamcinolone—psoriasis	0.00437	0.0191	CbGbCtD
Levonorgestrel—CYP3A4—Mycophenolate mofetil—psoriasis	0.00437	0.0191	CbGbCtD
Levonorgestrel—CYP3A4—Betamethasone—psoriasis	0.00375	0.0164	CbGbCtD
Levonorgestrel—CYP3A4—Prednisolone—psoriasis	0.0037	0.0162	CbGbCtD
Levonorgestrel—CYP3A4—Hydrocortisone—psoriasis	0.00351	0.0154	CbGbCtD
Levonorgestrel—CYP3A4—Prednisone—psoriasis	0.00349	0.0153	CbGbCtD
Levonorgestrel—CYP3A4—Cyclosporine—psoriasis	0.00331	0.0145	CbGbCtD
Levonorgestrel—CYP3A4—Dexamethasone—psoriasis	0.00218	0.00955	CbGbCtD
Levonorgestrel—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000296	0.0271	CbGpPWpGaD
Levonorgestrel—CYP19A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000292	0.0267	CbGpPWpGaD
Levonorgestrel—AR—Coregulation of Androgen receptor activity—ZMIZ1—psoriasis	0.000258	0.0236	CbGpPWpGaD
Levonorgestrel—CYP19A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00024	0.022	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—IL23A—psoriasis	0.00024	0.0219	CbGpPWpGaD
Levonorgestrel—PGR—Ovarian Infertility Genes—VDR—psoriasis	0.000218	0.0199	CbGpPWpGaD
Levonorgestrel—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000208	0.019	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—ZMIZ1—psoriasis	0.00019	0.0174	CbGpPWpGaD
Levonorgestrel—PGR—Nuclear Receptors—VDR—psoriasis	0.00019	0.0174	CbGpPWpGaD
Levonorgestrel—AR—Regulation of Androgen receptor activity—REL—psoriasis	0.000189	0.0172	CbGpPWpGaD
Levonorgestrel—AR—Regulation of Androgen receptor activity—CARM1—psoriasis	0.000186	0.017	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—TGFA—psoriasis	0.000172	0.0158	CbGpPWpGaD
Levonorgestrel—AR—Coregulation of Androgen receptor activity—CARM1—psoriasis	0.000166	0.0152	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—RUNX3—psoriasis	0.000156	0.0142	CbGpPWpGaD
Levonorgestrel—PGR—Nuclear Receptor transcription pathway—VDR—psoriasis	0.00015	0.0137	CbGpPWpGaD
Levonorgestrel—AR—Nuclear Receptors—VDR—psoriasis	0.000145	0.0132	CbGpPWpGaD
Levonorgestrel—CYP19A1—Ovarian Infertility Genes—VDR—psoriasis	0.000143	0.0131	CbGpPWpGaD
Levonorgestrel—PGR—Nuclear Receptors—PPARG—psoriasis	0.000132	0.0121	CbGpPWpGaD
Levonorgestrel—ESR1—Estrogen Receptor Pathway—JUN—psoriasis	0.00013	0.0119	CbGpPWpGaD
Levonorgestrel—CYP19A1—Biological oxidations—CYP2S1—psoriasis	0.000128	0.0117	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000126	0.0115	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000125	0.0114	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—CARM1—psoriasis	0.000123	0.0112	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—RUNX3—psoriasis	0.00012	0.011	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—NDUFA5—psoriasis	0.000118	0.0108	CbGpPWpGaD
Levonorgestrel—AR—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000114	0.0105	CbGpPWpGaD
Levonorgestrel—ESR1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000112	0.0103	CbGpPWpGaD
Levonorgestrel—ESR1—Nuclear Receptors—VDR—psoriasis	0.000111	0.0102	CbGpPWpGaD
Levonorgestrel—PGR—Validated nuclear estrogen receptor alpha network—PCNA—psoriasis	0.000111	0.0102	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.00011	0.0101	CbGpPWpGaD
Levonorgestrel—CYP19A1—Tryptophan metabolism—CAT—psoriasis	0.00011	0.0101	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—REL—psoriasis	0.00011	0.0101	CbGpPWpGaD
Levonorgestrel—PGR—Cellular roles of Anthrax toxin—TNF—psoriasis	0.000109	0.00996	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000107	0.00982	CbGpPWpGaD
Levonorgestrel—PGR—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000105	0.00957	CbGpPWpGaD
Levonorgestrel—AR—Nuclear Receptors—PPARG—psoriasis	0.000101	0.00923	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—CYP2S1—psoriasis	0.0001	0.00919	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	9.61e-05	0.00879	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—RUNX3—psoriasis	9.21e-05	0.00842	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	8.88e-05	0.00812	CbGpPWpGaD
Levonorgestrel—ESR1—Nuclear Receptor transcription pathway—VDR—psoriasis	8.81e-05	0.00806	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	8.66e-05	0.00792	CbGpPWpGaD
Levonorgestrel—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	8.65e-05	0.00791	CbGpPWpGaD
Levonorgestrel—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	8.53e-05	0.00781	CbGpPWpGaD
Levonorgestrel—ESR1—Estrogen signaling pathway—JUN—psoriasis	8.24e-05	0.00753	CbGpPWpGaD
Levonorgestrel—AR—Nuclear Receptor transcription pathway—PPARG—psoriasis	7.97e-05	0.00729	CbGpPWpGaD
Levonorgestrel—ESR1—Estrogen signaling pathway—NFKB1—psoriasis	7.93e-05	0.00725	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	7.9e-05	0.00722	CbGpPWpGaD
Levonorgestrel—ESR1—Nuclear Receptors—PPARG—psoriasis	7.77e-05	0.00711	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	7.68e-05	0.00703	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—IL13—psoriasis	7.27e-05	0.00665	CbGpPWpGaD
Levonorgestrel—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	7.01e-05	0.00641	CbGpPWpGaD
Levonorgestrel—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	6.92e-05	0.00633	CbGpPWpGaD
Levonorgestrel—AR—Notch-mediated HES/HEY network—CD4—psoriasis	6.74e-05	0.00617	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	6.67e-05	0.0061	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—IL10—psoriasis	6.65e-05	0.00608	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—TARS—psoriasis	6.64e-05	0.00608	CbGpPWpGaD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—PCNA—psoriasis	6.52e-05	0.00597	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—IL4—psoriasis	6.47e-05	0.00592	CbGpPWpGaD
Levonorgestrel—AR—FOXA1 transcription factor network—JUN—psoriasis	6.36e-05	0.00582	CbGpPWpGaD
Levonorgestrel—PGR—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	6.19e-05	0.00566	CbGpPWpGaD
Levonorgestrel—ESR1—Nuclear Receptor transcription pathway—PPARG—psoriasis	6.14e-05	0.00562	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	6.08e-05	0.00557	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	5.92e-05	0.00541	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	5.89e-05	0.00538	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—HLA-A—psoriasis	5.86e-05	0.00536	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—NOS2—psoriasis	5.85e-05	0.00535	CbGpPWpGaD
Levonorgestrel—AR—Regulation of Androgen receptor activity—JUN—psoriasis	5.48e-05	0.00502	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.27e-05	0.00482	CbGpPWpGaD
Levonorgestrel—AR—Notch-mediated HES/HEY network—STAT3—psoriasis	5.22e-05	0.00478	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—LEP—psoriasis	5.18e-05	0.00474	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—TARS—psoriasis	5.06e-05	0.00463	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—CARM1—psoriasis	4.91e-05	0.00449	CbGpPWpGaD
Levonorgestrel—ESR1—FOXA1 transcription factor network—JUN—psoriasis	4.9e-05	0.00448	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.59e-05	0.0042	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.55e-05	0.00417	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—IL10—psoriasis	4.55e-05	0.00416	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—IFNG—psoriasis	4.48e-05	0.0041	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—CARM1—psoriasis	4.34e-05	0.00397	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—psoriasis	4.24e-05	0.00388	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—CXCL8—psoriasis	4.17e-05	0.00381	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.13e-05	0.00378	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of Telomerase—IFNG—psoriasis	4e-05	0.00366	CbGpPWpGaD
Levonorgestrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	3.97e-05	0.00363	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	3.94e-05	0.00361	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—IFNG—psoriasis	3.91e-05	0.00358	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	3.91e-05	0.00357	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—TARS—psoriasis	3.9e-05	0.00357	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	3.89e-05	0.00355	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—JUN—psoriasis	3.88e-05	0.00355	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—TYK2—psoriasis	3.83e-05	0.0035	CbGpPWpGaD
Levonorgestrel—CYP3A4—Biological oxidations—CYP2S1—psoriasis	3.72e-05	0.00341	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	3.67e-05	0.00336	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—CXCL8—psoriasis	3.64e-05	0.00333	CbGpPWpGaD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	3.63e-05	0.00332	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—JUN—psoriasis	3.62e-05	0.00331	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.54e-05	0.00324	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.53e-05	0.00323	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of Telomerase—JUN—psoriasis	3.46e-05	0.00317	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—JUN—psoriasis	3.38e-05	0.00309	CbGpPWpGaD
Levonorgestrel—Anorexia—Hydrocortisone—psoriasis	3.36e-05	0.000338	CcSEcCtD
Levonorgestrel—Diarrhoea—Mycophenolic acid—psoriasis	3.36e-05	0.000337	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	3.34e-05	0.000336	CcSEcCtD
Levonorgestrel—Immune system disorder—Prednisone—psoriasis	3.34e-05	0.000335	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—NFKB1—psoriasis	3.33e-05	0.00305	CbGpPWpGaD
Levonorgestrel—Oedema—Triamcinolone—psoriasis	3.32e-05	0.000333	CcSEcCtD
Levonorgestrel—Vertigo—Betamethasone—psoriasis	3.32e-05	0.000333	CcSEcCtD
Levonorgestrel—Vertigo—Dexamethasone—psoriasis	3.32e-05	0.000333	CcSEcCtD
Levonorgestrel—Syncope—Betamethasone—psoriasis	3.31e-05	0.000333	CcSEcCtD
Levonorgestrel—Syncope—Dexamethasone—psoriasis	3.31e-05	0.000333	CcSEcCtD
Levonorgestrel—Constipation—Mycophenolate mofetil—psoriasis	3.31e-05	0.000332	CcSEcCtD
Levonorgestrel—Pain—Mycophenolate mofetil—psoriasis	3.31e-05	0.000332	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—CARM1—psoriasis	3.31e-05	0.00303	CbGpPWpGaD
Levonorgestrel—Arrhythmia—Prednisone—psoriasis	3.3e-05	0.000331	CcSEcCtD
Levonorgestrel—Infection—Triamcinolone—psoriasis	3.3e-05	0.000331	CcSEcCtD
Levonorgestrel—ESR1—LKB1 signaling events—TP53—psoriasis	3.3e-05	0.00301	CbGpPWpGaD
Levonorgestrel—Shock—Triamcinolone—psoriasis	3.27e-05	0.000328	CcSEcCtD
Levonorgestrel—Insomnia—Prednisolone—psoriasis	3.27e-05	0.000328	CcSEcCtD
Levonorgestrel—Alopecia—Prednisone—psoriasis	3.26e-05	0.000328	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Cyclosporine—psoriasis	3.24e-05	0.000326	CcSEcCtD
Levonorgestrel—Loss of consciousness—Dexamethasone—psoriasis	3.24e-05	0.000326	CcSEcCtD
Levonorgestrel—Loss of consciousness—Betamethasone—psoriasis	3.24e-05	0.000326	CcSEcCtD
Levonorgestrel—Dizziness—Mycophenolic acid—psoriasis	3.24e-05	0.000326	CcSEcCtD
Levonorgestrel—Mental disorder—Prednisone—psoriasis	3.24e-05	0.000325	CcSEcCtD
Levonorgestrel—Malnutrition—Prednisone—psoriasis	3.21e-05	0.000323	CcSEcCtD
Levonorgestrel—Erythema—Prednisone—psoriasis	3.21e-05	0.000323	CcSEcCtD
Levonorgestrel—CYP3A4—Tryptophan metabolism—CAT—psoriasis	3.21e-05	0.00294	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Hydrocortisone—psoriasis	3.21e-05	0.000323	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Triamcinolone—psoriasis	3.21e-05	0.000322	CcSEcCtD
Levonorgestrel—Insomnia—Hydrocortisone—psoriasis	3.19e-05	0.00032	CcSEcCtD
Levonorgestrel—Hypertension—Dexamethasone—psoriasis	3.19e-05	0.00032	CcSEcCtD
Levonorgestrel—Hypertension—Betamethasone—psoriasis	3.19e-05	0.00032	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	3.16e-05	0.000318	CcSEcCtD
Levonorgestrel—Urticaria—Cyclosporine—psoriasis	3.15e-05	0.000317	CcSEcCtD
Levonorgestrel—Myalgia—Dexamethasone—psoriasis	3.14e-05	0.000316	CcSEcCtD
Levonorgestrel—Myalgia—Betamethasone—psoriasis	3.14e-05	0.000316	CcSEcCtD
Levonorgestrel—Abdominal pain—Cyclosporine—psoriasis	3.14e-05	0.000315	CcSEcCtD
Levonorgestrel—Body temperature increased—Cyclosporine—psoriasis	3.14e-05	0.000315	CcSEcCtD
Levonorgestrel—AR—Androgen receptor signaling pathway—STAT3—psoriasis	3.13e-05	0.00287	CbGpPWpGaD
Levonorgestrel—Anxiety—Dexamethasone—psoriasis	3.13e-05	0.000315	CcSEcCtD
Levonorgestrel—Anxiety—Betamethasone—psoriasis	3.13e-05	0.000315	CcSEcCtD
Levonorgestrel—Vomiting—Mycophenolic acid—psoriasis	3.12e-05	0.000313	CcSEcCtD
Levonorgestrel—Discomfort—Dexamethasone—psoriasis	3.1e-05	0.000312	CcSEcCtD
Levonorgestrel—Discomfort—Betamethasone—psoriasis	3.1e-05	0.000312	CcSEcCtD
Levonorgestrel—Dyspepsia—Hydrocortisone—psoriasis	3.1e-05	0.000312	CcSEcCtD
Levonorgestrel—Haemoglobin—Methotrexate—psoriasis	3.1e-05	0.000312	CcSEcCtD
Levonorgestrel—Rash—Mycophenolic acid—psoriasis	3.09e-05	0.000311	CcSEcCtD
Levonorgestrel—Dermatitis—Mycophenolic acid—psoriasis	3.09e-05	0.00031	CcSEcCtD
Levonorgestrel—Pain—Prednisolone—psoriasis	3.09e-05	0.00031	CcSEcCtD
Levonorgestrel—Haemorrhage—Methotrexate—psoriasis	3.09e-05	0.00031	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—NFKB1—psoriasis	3.08e-05	0.00282	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HCAR2—psoriasis	3.08e-05	0.00282	CbGpPWpGaD
Levonorgestrel—Urticaria—Mycophenolate mofetil—psoriasis	3.07e-05	0.000309	CcSEcCtD
Levonorgestrel—Headache—Mycophenolic acid—psoriasis	3.07e-05	0.000309	CcSEcCtD
Levonorgestrel—Decreased appetite—Hydrocortisone—psoriasis	3.07e-05	0.000308	CcSEcCtD
Levonorgestrel—Pharyngitis—Methotrexate—psoriasis	3.06e-05	0.000308	CcSEcCtD
Levonorgestrel—Abdominal pain—Mycophenolate mofetil—psoriasis	3.06e-05	0.000307	CcSEcCtD
Levonorgestrel—Body temperature increased—Mycophenolate mofetil—psoriasis	3.06e-05	0.000307	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Methotrexate—psoriasis	3.05e-05	0.000306	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Hydrocortisone—psoriasis	3.04e-05	0.000306	CcSEcCtD
Levonorgestrel—Fatigue—Hydrocortisone—psoriasis	3.04e-05	0.000305	CcSEcCtD
Levonorgestrel—Urethral disorder—Methotrexate—psoriasis	3.03e-05	0.000304	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Triamcinolone—psoriasis	3.02e-05	0.000304	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—CAT—psoriasis	3.02e-05	0.00276	CbGpPWpGaD
Levonorgestrel—Pain—Hydrocortisone—psoriasis	3.02e-05	0.000303	CcSEcCtD
Levonorgestrel—Oedema—Dexamethasone—psoriasis	3.01e-05	0.000303	CcSEcCtD
Levonorgestrel—Oedema—Betamethasone—psoriasis	3.01e-05	0.000303	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	3.01e-05	0.00275	CbGpPWpGaD
Levonorgestrel—Insomnia—Triamcinolone—psoriasis	3e-05	0.000302	CcSEcCtD
Levonorgestrel—Infection—Dexamethasone—psoriasis	2.99e-05	0.000301	CcSEcCtD
Levonorgestrel—Infection—Betamethasone—psoriasis	2.99e-05	0.000301	CcSEcCtD
Levonorgestrel—Visual impairment—Methotrexate—psoriasis	2.97e-05	0.000299	CcSEcCtD
Levonorgestrel—Anaemia—Prednisone—psoriasis	2.97e-05	0.000298	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.97e-05	0.00271	CbGpPWpGaD
Levonorgestrel—Shock—Dexamethasone—psoriasis	2.96e-05	0.000298	CcSEcCtD
Levonorgestrel—Shock—Betamethasone—psoriasis	2.96e-05	0.000298	CcSEcCtD
Levonorgestrel—Dyspnoea—Triamcinolone—psoriasis	2.96e-05	0.000297	CcSEcCtD
Levonorgestrel—Nervous system disorder—Dexamethasone—psoriasis	2.95e-05	0.000297	CcSEcCtD
Levonorgestrel—Nervous system disorder—Betamethasone—psoriasis	2.95e-05	0.000297	CcSEcCtD
Levonorgestrel—Angioedema—Prednisone—psoriasis	2.94e-05	0.000295	CcSEcCtD
Levonorgestrel—Hypersensitivity—Cyclosporine—psoriasis	2.92e-05	0.000294	CcSEcCtD
Levonorgestrel—Dyspepsia—Triamcinolone—psoriasis	2.92e-05	0.000294	CcSEcCtD
Levonorgestrel—Erythema multiforme—Methotrexate—psoriasis	2.92e-05	0.000293	CcSEcCtD
Levonorgestrel—Nausea—Mycophenolic acid—psoriasis	2.91e-05	0.000293	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Betamethasone—psoriasis	2.91e-05	0.000293	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Dexamethasone—psoriasis	2.91e-05	0.000293	CcSEcCtD
Levonorgestrel—Vertigo—Prednisone—psoriasis	2.89e-05	0.00029	CcSEcCtD
Levonorgestrel—Eye disorder—Methotrexate—psoriasis	2.88e-05	0.00029	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Hydrocortisone—psoriasis	2.88e-05	0.00029	CcSEcCtD
Levonorgestrel—Syncope—Prednisone—psoriasis	2.88e-05	0.00029	CcSEcCtD
Levonorgestrel—Anorexia—Dexamethasone—psoriasis	2.87e-05	0.000288	CcSEcCtD
Levonorgestrel—Anorexia—Betamethasone—psoriasis	2.87e-05	0.000288	CcSEcCtD
Levonorgestrel—Urticaria—Prednisolone—psoriasis	2.87e-05	0.000288	CcSEcCtD
Levonorgestrel—Cardiac disorder—Methotrexate—psoriasis	2.86e-05	0.000288	CcSEcCtD
Levonorgestrel—Fatigue—Triamcinolone—psoriasis	2.86e-05	0.000288	CcSEcCtD
Levonorgestrel—Hypersensitivity—Mycophenolate mofetil—psoriasis	2.85e-05	0.000286	CcSEcCtD
Levonorgestrel—Asthenia—Cyclosporine—psoriasis	2.85e-05	0.000286	CcSEcCtD
Levonorgestrel—Pain—Triamcinolone—psoriasis	2.84e-05	0.000285	CcSEcCtD
Levonorgestrel—Loss of consciousness—Prednisone—psoriasis	2.83e-05	0.000284	CcSEcCtD
Levonorgestrel—Pruritus—Cyclosporine—psoriasis	2.81e-05	0.000282	CcSEcCtD
Levonorgestrel—Urticaria—Hydrocortisone—psoriasis	2.8e-05	0.000281	CcSEcCtD
Levonorgestrel—Immune system disorder—Methotrexate—psoriasis	2.79e-05	0.00028	CcSEcCtD
Levonorgestrel—Body temperature increased—Hydrocortisone—psoriasis	2.79e-05	0.00028	CcSEcCtD
Levonorgestrel—Abdominal pain—Hydrocortisone—psoriasis	2.79e-05	0.00028	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Methotrexate—psoriasis	2.78e-05	0.000279	CcSEcCtD
Levonorgestrel—Asthenia—Mycophenolate mofetil—psoriasis	2.78e-05	0.000279	CcSEcCtD
Levonorgestrel—Hypertension—Prednisone—psoriasis	2.78e-05	0.000279	CcSEcCtD
Levonorgestrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.77e-05	0.00253	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—STAT3—psoriasis	2.77e-05	0.00253	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Betamethasone—psoriasis	2.74e-05	0.000276	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Dexamethasone—psoriasis	2.74e-05	0.000276	CcSEcCtD
Levonorgestrel—Pruritus—Mycophenolate mofetil—psoriasis	2.74e-05	0.000275	CcSEcCtD
Levonorgestrel—Myalgia—Prednisone—psoriasis	2.74e-05	0.000275	CcSEcCtD
Levonorgestrel—Anxiety—Prednisone—psoriasis	2.73e-05	0.000274	CcSEcCtD
Levonorgestrel—Alopecia—Methotrexate—psoriasis	2.73e-05	0.000274	CcSEcCtD
Levonorgestrel—Insomnia—Dexamethasone—psoriasis	2.72e-05	0.000274	CcSEcCtD
Levonorgestrel—Insomnia—Betamethasone—psoriasis	2.72e-05	0.000274	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.72e-05	0.00249	CbGpPWpGaD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	2.72e-05	0.000273	CcSEcCtD
Levonorgestrel—Diarrhoea—Cyclosporine—psoriasis	2.71e-05	0.000273	CcSEcCtD
Levonorgestrel—Discomfort—Prednisone—psoriasis	2.7e-05	0.000272	CcSEcCtD
Levonorgestrel—Mental disorder—Methotrexate—psoriasis	2.7e-05	0.000272	CcSEcCtD
Levonorgestrel—Erythema—Methotrexate—psoriasis	2.69e-05	0.00027	CcSEcCtD
Levonorgestrel—Malnutrition—Methotrexate—psoriasis	2.69e-05	0.00027	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—TAGAP—psoriasis	2.67e-05	0.00244	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Prednisolone—psoriasis	2.66e-05	0.000267	CcSEcCtD
Levonorgestrel—Dyspepsia—Dexamethasone—psoriasis	2.65e-05	0.000266	CcSEcCtD
Levonorgestrel—Dyspepsia—Betamethasone—psoriasis	2.65e-05	0.000266	CcSEcCtD
Levonorgestrel—Diarrhoea—Mycophenolate mofetil—psoriasis	2.65e-05	0.000266	CcSEcCtD
Levonorgestrel—Urticaria—Triamcinolone—psoriasis	2.64e-05	0.000265	CcSEcCtD
Levonorgestrel—Body temperature increased—Triamcinolone—psoriasis	2.62e-05	0.000264	CcSEcCtD
Levonorgestrel—Dizziness—Cyclosporine—psoriasis	2.62e-05	0.000264	CcSEcCtD
Levonorgestrel—Oedema—Prednisone—psoriasis	2.62e-05	0.000264	CcSEcCtD
Levonorgestrel—Decreased appetite—Dexamethasone—psoriasis	2.62e-05	0.000263	CcSEcCtD
Levonorgestrel—Decreased appetite—Betamethasone—psoriasis	2.62e-05	0.000263	CcSEcCtD
Levonorgestrel—Infection—Prednisone—psoriasis	2.61e-05	0.000262	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Dexamethasone—psoriasis	2.6e-05	0.000261	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Betamethasone—psoriasis	2.6e-05	0.000261	CcSEcCtD
Levonorgestrel—Back pain—Methotrexate—psoriasis	2.6e-05	0.000261	CcSEcCtD
Levonorgestrel—Hypersensitivity—Hydrocortisone—psoriasis	2.6e-05	0.000261	CcSEcCtD
Levonorgestrel—Fatigue—Betamethasone—psoriasis	2.6e-05	0.000261	CcSEcCtD
Levonorgestrel—Fatigue—Dexamethasone—psoriasis	2.6e-05	0.000261	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—VDR—psoriasis	2.59e-05	0.00237	CbGpPWpGaD
Levonorgestrel—Shock—Prednisone—psoriasis	2.58e-05	0.000259	CcSEcCtD
Levonorgestrel—Pain—Dexamethasone—psoriasis	2.58e-05	0.000259	CcSEcCtD
Levonorgestrel—Pain—Betamethasone—psoriasis	2.58e-05	0.000259	CcSEcCtD
Levonorgestrel—Nervous system disorder—Prednisone—psoriasis	2.57e-05	0.000258	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—NDUFA5—psoriasis	2.57e-05	0.00235	CbGpPWpGaD
Levonorgestrel—Dizziness—Mycophenolate mofetil—psoriasis	2.56e-05	0.000257	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—CARM1—psoriasis	2.55e-05	0.00233	CbGpPWpGaD
Levonorgestrel—Skin disorder—Prednisone—psoriasis	2.55e-05	0.000256	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Prednisone—psoriasis	2.54e-05	0.000255	CcSEcCtD
Levonorgestrel—Asthenia—Hydrocortisone—psoriasis	2.53e-05	0.000254	CcSEcCtD
Levonorgestrel—Vomiting—Cyclosporine—psoriasis	2.52e-05	0.000253	CcSEcCtD
Levonorgestrel—Rash—Cyclosporine—psoriasis	2.5e-05	0.000251	CcSEcCtD
Levonorgestrel—Anorexia—Prednisone—psoriasis	2.5e-05	0.000251	CcSEcCtD
Levonorgestrel—Dermatitis—Cyclosporine—psoriasis	2.5e-05	0.000251	CcSEcCtD
Levonorgestrel—Pruritus—Hydrocortisone—psoriasis	2.49e-05	0.000251	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—CXCL8—psoriasis	2.49e-05	0.00227	CbGpPWpGaD
Levonorgestrel—Headache—Cyclosporine—psoriasis	2.49e-05	0.00025	CcSEcCtD
Levonorgestrel—Anaemia—Methotrexate—psoriasis	2.48e-05	0.000249	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Dexamethasone—psoriasis	2.46e-05	0.000247	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Betamethasone—psoriasis	2.46e-05	0.000247	CcSEcCtD
Levonorgestrel—Vomiting—Mycophenolate mofetil—psoriasis	2.46e-05	0.000247	CcSEcCtD
Levonorgestrel—Hypersensitivity—Triamcinolone—psoriasis	2.45e-05	0.000246	CcSEcCtD
Levonorgestrel—Rash—Mycophenolate mofetil—psoriasis	2.44e-05	0.000245	CcSEcCtD
Levonorgestrel—Dermatitis—Mycophenolate mofetil—psoriasis	2.44e-05	0.000245	CcSEcCtD
Levonorgestrel—Headache—Mycophenolate mofetil—psoriasis	2.42e-05	0.000244	CcSEcCtD
Levonorgestrel—Vertigo—Methotrexate—psoriasis	2.41e-05	0.000242	CcSEcCtD
Levonorgestrel—Diarrhoea—Hydrocortisone—psoriasis	2.41e-05	0.000242	CcSEcCtD
Levonorgestrel—Urticaria—Betamethasone—psoriasis	2.39e-05	0.00024	CcSEcCtD
Levonorgestrel—Urticaria—Dexamethasone—psoriasis	2.39e-05	0.00024	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.39e-05	0.00219	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Prednisone—psoriasis	2.39e-05	0.00024	CcSEcCtD
Levonorgestrel—Dizziness—Prednisolone—psoriasis	2.39e-05	0.00024	CcSEcCtD
Levonorgestrel—Asthenia—Triamcinolone—psoriasis	2.38e-05	0.000239	CcSEcCtD
Levonorgestrel—Abdominal pain—Betamethasone—psoriasis	2.38e-05	0.000239	CcSEcCtD
Levonorgestrel—Body temperature increased—Betamethasone—psoriasis	2.38e-05	0.000239	CcSEcCtD
Levonorgestrel—Abdominal pain—Dexamethasone—psoriasis	2.38e-05	0.000239	CcSEcCtD
Levonorgestrel—Body temperature increased—Dexamethasone—psoriasis	2.38e-05	0.000239	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—JUN—psoriasis	2.37e-05	0.00217	CbGpPWpGaD
Levonorgestrel—Insomnia—Prednisone—psoriasis	2.37e-05	0.000238	CcSEcCtD
Levonorgestrel—Nausea—Cyclosporine—psoriasis	2.36e-05	0.000237	CcSEcCtD
Levonorgestrel—Pruritus—Triamcinolone—psoriasis	2.35e-05	0.000236	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—APOE—psoriasis	2.35e-05	0.00215	CbGpPWpGaD
Levonorgestrel—Cough—Methotrexate—psoriasis	2.34e-05	0.000235	CcSEcCtD
Levonorgestrel—ESR1—ATF-2 transcription factor network—IL6—psoriasis	2.34e-05	0.00214	CbGpPWpGaD
Levonorgestrel—Dizziness—Hydrocortisone—psoriasis	2.33e-05	0.000234	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—JUN—psoriasis	2.31e-05	0.00211	CbGpPWpGaD
Levonorgestrel—Dyspepsia—Prednisone—psoriasis	2.31e-05	0.000232	CcSEcCtD
Levonorgestrel—Nausea—Mycophenolate mofetil—psoriasis	2.3e-05	0.000231	CcSEcCtD
Levonorgestrel—Chest pain—Methotrexate—psoriasis	2.29e-05	0.00023	CcSEcCtD
Levonorgestrel—Myalgia—Methotrexate—psoriasis	2.29e-05	0.00023	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.28e-05	0.00209	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	2.28e-05	0.00209	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Prednisone—psoriasis	2.28e-05	0.000229	CcSEcCtD
Levonorgestrel—Rash—Prednisolone—psoriasis	2.28e-05	0.000229	CcSEcCtD
Levonorgestrel—Dermatitis—Prednisolone—psoriasis	2.27e-05	0.000228	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	2.27e-05	0.000228	CcSEcCtD
Levonorgestrel—Fatigue—Prednisone—psoriasis	2.26e-05	0.000227	CcSEcCtD
Levonorgestrel—Headache—Prednisolone—psoriasis	2.26e-05	0.000227	CcSEcCtD
Levonorgestrel—Discomfort—Methotrexate—psoriasis	2.26e-05	0.000227	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—TYK2—psoriasis	2.25e-05	0.00205	CbGpPWpGaD
Levonorgestrel—Constipation—Prednisone—psoriasis	2.24e-05	0.000225	CcSEcCtD
Levonorgestrel—Vomiting—Hydrocortisone—psoriasis	2.24e-05	0.000225	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—TP53—psoriasis	2.23e-05	0.00204	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—NFKB1—psoriasis	2.23e-05	0.00204	CbGpPWpGaD
Levonorgestrel—Rash—Hydrocortisone—psoriasis	2.22e-05	0.000223	CcSEcCtD
Levonorgestrel—Dermatitis—Hydrocortisone—psoriasis	2.22e-05	0.000223	CcSEcCtD
Levonorgestrel—Headache—Hydrocortisone—psoriasis	2.21e-05	0.000222	CcSEcCtD
Levonorgestrel—Dizziness—Triamcinolone—psoriasis	2.2e-05	0.000221	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—CYP2S1—psoriasis	2.18e-05	0.002	CbGpPWpGaD
Levonorgestrel—Infection—Methotrexate—psoriasis	2.18e-05	0.000219	CcSEcCtD
Levonorgestrel—Asthenia—Dexamethasone—psoriasis	2.16e-05	0.000217	CcSEcCtD
Levonorgestrel—Asthenia—Betamethasone—psoriasis	2.16e-05	0.000217	CcSEcCtD
Levonorgestrel—Nervous system disorder—Methotrexate—psoriasis	2.15e-05	0.000216	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Prednisone—psoriasis	2.15e-05	0.000215	CcSEcCtD
Levonorgestrel—Nausea—Prednisolone—psoriasis	2.14e-05	0.000215	CcSEcCtD
Levonorgestrel—Pruritus—Dexamethasone—psoriasis	2.13e-05	0.000214	CcSEcCtD
Levonorgestrel—Pruritus—Betamethasone—psoriasis	2.13e-05	0.000214	CcSEcCtD
Levonorgestrel—Skin disorder—Methotrexate—psoriasis	2.13e-05	0.000214	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Methotrexate—psoriasis	2.12e-05	0.000213	CcSEcCtD
Levonorgestrel—Vomiting—Triamcinolone—psoriasis	2.11e-05	0.000212	CcSEcCtD
Levonorgestrel—Nausea—Hydrocortisone—psoriasis	2.09e-05	0.00021	CcSEcCtD
Levonorgestrel—Rash—Triamcinolone—psoriasis	2.09e-05	0.00021	CcSEcCtD
Levonorgestrel—Dermatitis—Triamcinolone—psoriasis	2.09e-05	0.00021	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—CARM1—psoriasis	2.09e-05	0.00191	CbGpPWpGaD
Levonorgestrel—Anorexia—Methotrexate—psoriasis	2.09e-05	0.00021	CcSEcCtD
Levonorgestrel—Urticaria—Prednisone—psoriasis	2.08e-05	0.000209	CcSEcCtD
Levonorgestrel—Headache—Triamcinolone—psoriasis	2.08e-05	0.000209	CcSEcCtD
Levonorgestrel—Body temperature increased—Prednisone—psoriasis	2.07e-05	0.000208	CcSEcCtD
Levonorgestrel—Abdominal pain—Prednisone—psoriasis	2.07e-05	0.000208	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	2.07e-05	0.0019	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Betamethasone—psoriasis	2.06e-05	0.000207	CcSEcCtD
Levonorgestrel—Diarrhoea—Dexamethasone—psoriasis	2.06e-05	0.000207	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—IL6—psoriasis	2.04e-05	0.00187	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—PPARG—psoriasis	2.04e-05	0.00187	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—JUN—psoriasis	2.04e-05	0.00187	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.02e-05	0.00185	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Methotrexate—psoriasis	2e-05	0.000201	CcSEcCtD
Levonorgestrel—Dizziness—Dexamethasone—psoriasis	1.99e-05	0.0002	CcSEcCtD
Levonorgestrel—Dizziness—Betamethasone—psoriasis	1.99e-05	0.0002	CcSEcCtD
Levonorgestrel—Insomnia—Methotrexate—psoriasis	1.98e-05	0.000199	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—VDR—psoriasis	1.98e-05	0.00181	CbGpPWpGaD
Levonorgestrel—Nausea—Triamcinolone—psoriasis	1.97e-05	0.000198	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.97e-05	0.0018	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	1.97e-05	0.0018	CbGpPWpGaD
Levonorgestrel—Dyspnoea—Methotrexate—psoriasis	1.95e-05	0.000196	CcSEcCtD
Levonorgestrel—Somnolence—Methotrexate—psoriasis	1.95e-05	0.000196	CcSEcCtD
Levonorgestrel—Hypersensitivity—Prednisone—psoriasis	1.93e-05	0.000194	CcSEcCtD
Levonorgestrel—Dyspepsia—Methotrexate—psoriasis	1.93e-05	0.000194	CcSEcCtD
Levonorgestrel—Vomiting—Dexamethasone—psoriasis	1.92e-05	0.000192	CcSEcCtD
Levonorgestrel—Vomiting—Betamethasone—psoriasis	1.92e-05	0.000192	CcSEcCtD
Levonorgestrel—Decreased appetite—Methotrexate—psoriasis	1.91e-05	0.000191	CcSEcCtD
Levonorgestrel—Rash—Betamethasone—psoriasis	1.9e-05	0.000191	CcSEcCtD
Levonorgestrel—Rash—Dexamethasone—psoriasis	1.9e-05	0.000191	CcSEcCtD
Levonorgestrel—Dermatitis—Betamethasone—psoriasis	1.9e-05	0.000191	CcSEcCtD
Levonorgestrel—Dermatitis—Dexamethasone—psoriasis	1.9e-05	0.000191	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Methotrexate—psoriasis	1.89e-05	0.00019	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.89e-05	0.00173	CbGpPWpGaD
Levonorgestrel—Fatigue—Methotrexate—psoriasis	1.89e-05	0.00019	CcSEcCtD
Levonorgestrel—Headache—Betamethasone—psoriasis	1.89e-05	0.00019	CcSEcCtD
Levonorgestrel—Headache—Dexamethasone—psoriasis	1.89e-05	0.00019	CcSEcCtD
Levonorgestrel—Asthenia—Prednisone—psoriasis	1.88e-05	0.000189	CcSEcCtD
Levonorgestrel—Pain—Methotrexate—psoriasis	1.87e-05	0.000188	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—IL6—psoriasis	1.87e-05	0.00171	CbGpPWpGaD
Levonorgestrel—Pruritus—Prednisone—psoriasis	1.86e-05	0.000186	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—JUN—psoriasis	1.83e-05	0.00167	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—PPARG—psoriasis	1.81e-05	0.00165	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HCAR2—psoriasis	1.81e-05	0.00165	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Prednisone—psoriasis	1.79e-05	0.00018	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Methotrexate—psoriasis	1.79e-05	0.00018	CcSEcCtD
Levonorgestrel—Nausea—Betamethasone—psoriasis	1.79e-05	0.00018	CcSEcCtD
Levonorgestrel—Nausea—Dexamethasone—psoriasis	1.79e-05	0.00018	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	1.78e-05	0.00163	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	1.76e-05	0.00161	CbGpPWpGaD
Levonorgestrel—Urticaria—Methotrexate—psoriasis	1.74e-05	0.000175	CcSEcCtD
Levonorgestrel—Dizziness—Prednisone—psoriasis	1.73e-05	0.000174	CcSEcCtD
Levonorgestrel—Body temperature increased—Methotrexate—psoriasis	1.73e-05	0.000174	CcSEcCtD
Levonorgestrel—Abdominal pain—Methotrexate—psoriasis	1.73e-05	0.000174	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—TNF—psoriasis	1.73e-05	0.00158	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.72e-05	0.00157	CbGpPWpGaD
Levonorgestrel—Vomiting—Prednisone—psoriasis	1.67e-05	0.000168	CcSEcCtD
Levonorgestrel—Rash—Prednisone—psoriasis	1.65e-05	0.000166	CcSEcCtD
Levonorgestrel—Dermatitis—Prednisone—psoriasis	1.65e-05	0.000166	CcSEcCtD
Levonorgestrel—Headache—Prednisone—psoriasis	1.64e-05	0.000165	CcSEcCtD
Levonorgestrel—Hypersensitivity—Methotrexate—psoriasis	1.62e-05	0.000162	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—CCL20—psoriasis	1.6e-05	0.00146	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	1.6e-05	0.00146	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—CARM1—psoriasis	1.59e-05	0.00146	CbGpPWpGaD
Levonorgestrel—Asthenia—Methotrexate—psoriasis	1.57e-05	0.000158	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—TP53—psoriasis	1.57e-05	0.00143	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TAGAP—psoriasis	1.57e-05	0.00143	CbGpPWpGaD
Levonorgestrel—Nausea—Prednisone—psoriasis	1.56e-05	0.000157	CcSEcCtD
Levonorgestrel—Pruritus—Methotrexate—psoriasis	1.55e-05	0.000156	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—VDR—psoriasis	1.52e-05	0.00139	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.51e-05	0.00139	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Methotrexate—psoriasis	1.5e-05	0.000151	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.47e-05	0.00135	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.46e-05	0.00133	CbGpPWpGaD
Levonorgestrel—Dizziness—Methotrexate—psoriasis	1.45e-05	0.000146	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—IL6—psoriasis	1.4e-05	0.00128	CbGpPWpGaD
Levonorgestrel—Vomiting—Methotrexate—psoriasis	1.39e-05	0.00014	CcSEcCtD
Levonorgestrel—Rash—Methotrexate—psoriasis	1.38e-05	0.000139	CcSEcCtD
Levonorgestrel—Dermatitis—Methotrexate—psoriasis	1.38e-05	0.000139	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—PPARG—psoriasis	1.38e-05	0.00126	CbGpPWpGaD
Levonorgestrel—Headache—Methotrexate—psoriasis	1.37e-05	0.000138	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—TP53—psoriasis	1.35e-05	0.00123	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.32e-05	0.00121	CbGpPWpGaD
Levonorgestrel—Nausea—Methotrexate—psoriasis	1.3e-05	0.000131	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.3e-05	0.00119	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—VDR—psoriasis	1.25e-05	0.00114	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—CARM1—psoriasis	1.23e-05	0.00112	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—TP53—psoriasis	1.21e-05	0.0011	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.14e-05	0.00105	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.13e-05	0.00104	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—IL6—psoriasis	1.1e-05	0.001	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CARM1—psoriasis	1.07e-05	0.000975	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—PPARG—psoriasis	1.06e-05	0.00097	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1e-05	0.000915	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.96e-06	0.000911	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—VDR—psoriasis	9.51e-06	0.00087	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCL20—psoriasis	9.38e-06	0.000858	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SOCS1—psoriasis	8.8e-06	0.000805	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—PPARG—psoriasis	8.7e-06	0.000796	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NDUFA5—psoriasis	7.49e-06	0.000685	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—VDR—psoriasis	7.33e-06	0.00067	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—PPARG—psoriasis	6.63e-06	0.000606	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CAT—psoriasis	6.55e-06	0.0006	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—LEP—psoriasis	6.5e-06	0.000594	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—APOE—psoriasis	6.5e-06	0.000594	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP2S1—psoriasis	6.37e-06	0.000582	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NFKBIA—psoriasis	6.05e-06	0.000554	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SOCS1—psoriasis	5.17e-06	0.000473	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PPARG—psoriasis	5.11e-06	0.000467	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—APOE—psoriasis	5.09e-06	0.000466	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TYK2—psoriasis	4.96e-06	0.000454	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PPARG—psoriasis	4.44e-06	0.000406	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCL8—psoriasis	4.32e-06	0.000395	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—JUN—psoriasis	4.01e-06	0.000367	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NFKB1—psoriasis	3.86e-06	0.000353	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—APOE—psoriasis	3.81e-06	0.000349	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—LEP—psoriasis	3.81e-06	0.000349	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NFKBIA—psoriasis	3.55e-06	0.000325	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—VEGFA—psoriasis	3.51e-06	0.000321	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—STAT3—psoriasis	3.47e-06	0.000318	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CARM1—psoriasis	3.11e-06	0.000284	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TYK2—psoriasis	2.91e-06	0.000266	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TP53—psoriasis	2.65e-06	0.000242	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCL8—psoriasis	2.53e-06	0.000232	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL6—psoriasis	2.42e-06	0.000222	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—JUN—psoriasis	2.36e-06	0.000215	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NFKB1—psoriasis	2.27e-06	0.000207	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—VEGFA—psoriasis	2.06e-06	0.000188	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—STAT3—psoriasis	2.04e-06	0.000186	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CAT—psoriasis	1.91e-06	0.000175	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TP53—psoriasis	1.55e-06	0.000142	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—APOE—psoriasis	1.49e-06	0.000136	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL6—psoriasis	1.42e-06	0.00013	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PPARG—psoriasis	1.29e-06	0.000118	CbGpPWpGaD
